These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7903542)

  • 1. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group.
    Clin Investig; 1994 Jan; 72(2):111-6. PubMed ID: 8186655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV infection and zidovudine use in childbearing women.
    Sia J; Paul S; Martin RM; Cross H
    Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
    Ding YY; Jia WQ; Wang JS; Dong SL; Yang QH; Zhou RY; Qu SX; Lu LX; Wei J; Qiao XC; Gao MY; Guo XL; Zhang TJ; Wu ZY; He N
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec; 29(12):1176-80. PubMed ID: 19173958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of the survival benefit of zidovudine therapy in HIV infection.
    Moore RD; Keruly JC; Chaisson RE
    Arch Intern Med; 1996 May; 156(10):1073-7. PubMed ID: 8638994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive CD4 cell depletion and death in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Moyle G; Gazzard BG
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):927-9. PubMed ID: 8100272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
    Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
    Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research.
    Gardner LI; Harrison SH; Hendrix CW; Blatt SP; Wagner KF; Chung RC; Harris RW; Cohn DL; Burke DS; Mayers DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):345-53. PubMed ID: 9525436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.
    Wandeler G; Gsponer T; Mulenga L; Garone D; Wood R; Maskew M; Prozesky H; Hoffmann C; Ehmer J; Dickinson D; Davies MA; Egger M; Keiser O;
    AIDS; 2013 Sep; 27(14):2225-32. PubMed ID: 23660577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.